What is the clinical utility of the Combined Positive Score (CPS) for PDL-1 expression when considering pembrolizumab for gastric cancer?
How do you interpret results when IHC is < 1% but CPS > 1?
Community PollStarted
For a gastric cancer patient progressing on FU/platinum and then ramucirumab plus taxol, at what CPS score do you decide to use Pembrolizumab?
38 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on
From multiple studies, it is very clear that higher staining for PDL-1 on tumors and immune cells (combined expression, resulting in the CPS (combined positive score)) is correlated with increased Response Rate, PFS and clinical benefit of anti-PD1 drugs. Pembrolizumab is approved for gastric cancer...
Join for free or sign in to see the full answer